A Phase II Study of CC-5013 in Myelofibrosis
NCT00087672
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
41
Enrollment
OTHER
Sponsor class
Conditions
Myelofibrosis
Interventions
DRUG:
CC-5013
Sponsor
M.D. Anderson Cancer Center
Collaborators
[object Object]